Clinical Trial Update: Sevelamer for Reducing Endotoxemia and Immune Activation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sevelamer for reducing endotoxemia and immune activation in HIV-1 infection has completed with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Sevelamer (sevelamer hydrochloride)

Snippet

Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2013-11-25